Activist Investor Pushes for Sale of Ashland Inc to Boost Share Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: Newsfilter
- Increased Shareholder Pressure: Activist investor Ancora Alternatives has built a significant stake in Ashland Inc (ASH.N) and argues that a sale could boost the share price by at least 30%, demonstrating strong confidence in the company's future value.
- Background of Stock Decline: Since hitting a high in December 2022, Ashland's stock price has tumbled roughly 50%, now trading near $57.50, reflecting investor punishment for disappointing performance, with a market value of only $2.7 billion.
- Acquisition Potential Analysis: Ancora forecasts that a sale could push the stock price to at least $76, marking a 31% increase, indicating that the company's intrinsic value remains underappreciated amid current trading discounts and growth challenges.
- Possibility of Management Changes: Ancora is prepared to launch a proxy fight during the upcoming shareholder nomination window if constructive dialogue with management does not yield a resolution, aiming to add fresh leadership to the board to ensure proper fiduciary oversight.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASH
Wall Street analysts forecast ASH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 64.360
Low
53.00
Averages
66.67
High
73.00
Current: 64.360
Low
53.00
Averages
66.67
High
73.00
About ASH
Ashland Inc. is a global additives and specialty ingredients company. The Company serves customers in a range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceuticals. The Company's segments include Life Sciences, Personal Care, Specialty Additives, and Intermediates. The Life Sciences segment consists of pharmaceuticals, nutrition, agricultural chemicals, diagnostic films and fine chemicals. The Personal Care segment includes functionals, microbial protectants (preservatives), skin care, sun care, oral care, hair care and household solutions. The Specialty Additives segment consists of rheology and performance-enhancing additives serving the architectural coatings, construction, energy, automotive and various industrial markets. The Intermediates segment consists of the production of 1,4 butanediol (BDO) and related derivatives, including n-methyl pyrrolidone.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stock Price Surge: Ashland Inc. (ASH) shares rose 4.2%, reflecting market optimism regarding Cruiser Capital's push for a sale, indicating investor expectations for potential value realization.
- Asset Appeal: According to Cruiser Capital's letter, while Ashland possesses attractive assets, its lack of scale has hindered maximizing shareholder value, a perspective that may prompt the company to consider a sale to enhance market performance.
- Activist Investor Involvement: Activist investor Ancora Alternatives disclosed a significant stake in Ashland earlier this month, believing the company could achieve a sale price of at least $76 per share, representing a 31% increase from recent levels, further intensifying market focus on a potential sale.
- Proxy Contest Threat: Cruiser Capital threatened to nominate dissident director candidates if the Ashland board does not engage in a credible sale process by September 15, demonstrating the activist investors' strong intent to influence corporate governance and strategic direction.
See More
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
- Stock Performance: Ashland Inc shares traded at $64.90, surpassing the 12-month analyst target price of $64.33, indicating increased market confidence in the company.
- Analyst Reactions: When a stock hits an analyst's target, they may downgrade or raise their price target, reflecting differing views on fundamental business developments, which could influence investor decisions.
- Target Price Distribution: Among the 12 analysts covered by Zacks, target prices range from $50.00 to $75.00, with a standard deviation of $6.678, highlighting varying expectations for Ashland Inc's future performance.
- Investor Signal: With the stock price exceeding the average target, investors are prompted to reassess the company, considering whether the current valuation is justified or if it’s time to take profits to mitigate risk.
See More
- Board Commitment: Ashland's Board of Directors and management are dedicated to creating sustainable value for all shareholders, emphasizing respect for diverse perspectives and welcoming constructive feedback, indicating the company's commitment to shareholder communication.
- Ongoing Dialogue Plan: Although Ancora did not engage with Ashland prior to its presentation, Ashland intends to engage with them consistently to strengthen ongoing dialogue with investors, demonstrating the company's focus on shareholder relations.
- Focus on Growth Strategy: Ashland is concentrating on globalization, innovation, and investment while improving operational performance and cash generation, with expectations that these priorities will drive the company’s transformation into sustained financial and operational performance.
- Strategic Evaluation Mechanism: The Board regularly evaluates the company's strategy and value creation opportunities, including reviews of the operating plan, portfolio priorities, and capital policy, ensuring decisions align with the best interests of the company and all shareholders.
See More
- Activist Investor Stake: Activist investor Ancora Alternatives began building its position in Ashland (ASH) in April, leading to a 6.3% rise in share price, reflecting market confidence in the company's future prospects.
- Potential Sale Value: Ancora believes Ashland could be sold for at least $76 per share, representing a 31% increase from current levels, indicating the market's recognition of its intrinsic value and potential appeal to strategic investors.
- Proxy Fight Preparedness: Ancora is ready to initiate a proxy fight if Ashland does not make tangible progress toward a deal by the September director nomination window, highlighting its strong focus on corporate governance.
- Financial Outlook: Ashland projects fiscal 2026 sales between $1.835 billion and $1.87 billion, with adjusted EBITDA of $385 million to $400 million, despite facing $10 million to $12 million in savings cuts due to delays in the Hopewell project.
See More
- Increased Shareholder Pressure: Activist investor Ancora Alternatives has built a significant stake in Ashland Inc (ASH.N) and argues that a sale could boost the share price by at least 30%, demonstrating strong confidence in the company's future value.
- Background of Stock Decline: Since hitting a high in December 2022, Ashland's stock price has tumbled roughly 50%, now trading near $57.50, reflecting investor punishment for disappointing performance, with a market value of only $2.7 billion.
- Acquisition Potential Analysis: Ancora forecasts that a sale could push the stock price to at least $76, marking a 31% increase, indicating that the company's intrinsic value remains underappreciated amid current trading discounts and growth challenges.
- Possibility of Management Changes: Ancora is prepared to launch a proxy fight during the upcoming shareholder nomination window if constructive dialogue with management does not yield a resolution, aiming to add fresh leadership to the board to ensure proper fiduciary oversight.
See More







